Symbols / KPTI
KPTI Chart
About
Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 184.72M |
| Enterprise Value | 426.92M | Income | -196.04M | Sales | 146.07M |
| Book/sh | -16.00 | Cash/sh | 3.48 | Dividend Yield | — |
| Payout | 0.00% | Employees | 228 | IPO | — |
| P/E | — | Forward P/E | -4.01 | PEG | — |
| P/S | 1.26 | P/B | -0.63 | P/C | — |
| EV/EBITDA | -4.72 | EV/Sales | 2.92 | Quick Ratio | 0.98 |
| Current Ratio | 1.12 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -17.93 | EPS next Y | -2.51 | EPS Growth | — |
| Revenue Growth | 11.60% | Earnings | 2026-05-11 | ROA | -41.56% |
| ROE | — | ROIC | — | Gross Margin | 9.93% |
| Oper. Margin | -52.36% | Profit Margin | -134.21% | Shs Outstand | 18.34M |
| Shs Float | 16.30M | Short Float | 8.49% | Short Ratio | 3.08 |
| Short Interest | — | 52W High | 10.99 | 52W Low | 3.51 |
| Beta | 0.22 | Avg Volume | 428.83K | Volume | 609.74K |
| Target Price | $15.33 | Recom | Buy | Prev Close | $10.03 |
| Price | $10.07 | Change | 0.40% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.33
Mean price target
2. Current target
$10.07
Latest analyst target
3. DCF / Fair value
$-48.50
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$10.07
Low
$6.00
High
$23.00
Mean
$15.33
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-18 | reit | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-02-05 | init | Cantor Fitzgerald | — → Overweight | — |
| 2025-11-04 | main | RBC Capital | Outperform → Outperform | $19 |
| 2025-10-13 | up | HC Wainwright & Co. | Neutral → Buy | $15 |
| 2025-10-09 | reit | Piper Sandler | Overweight → Overweight | $12 |
| 2025-10-09 | main | Baird | Outperform → Outperform | $21 |
| 2025-08-12 | main | Baird | Outperform → Outperform | $25 |
| 2025-07-16 | down | HC Wainwright & Co. | Buy → Neutral | — |
| 2025-05-13 | main | RBC Capital | Outperform → Outperform | $33 |
| 2025-05-13 | main | Barclays | Overweight → Overweight | $10 |
| 2025-05-13 | main | Baird | Outperform → Outperform | $42 |
| 2025-03-03 | main | Baird | Outperform → Outperform | $54 |
| 2025-02-26 | main | HC Wainwright & Co. | Buy → Buy | $56 |
| 2025-02-20 | reit | RBC Capital | Outperform → Outperform | $3 |
| 2025-02-20 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2025-02-10 | reit | RBC Capital | Outperform → Outperform | $3 |
| 2025-01-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-06 | main | Piper Sandler | Overweight → Overweight | $5 |
| 2024-11-06 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-01 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
- Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis - PR Newswire Wed, 08 Oct 2025 07
- $KPTI stock is up 28% today. Here's what we see in our data. - Quiver Quantitative hu, 12 Feb 2026 08
- Wall Street Analysts Believe Karyopharm Therapeutics (KPTI) Could Rally 56.06%: Here's is How to Trade - Zacks Investment Research hu, 19 Feb 2026 06
- KPTI Receives Reiterated "Buy" Rating from HC Wainwright & Co. | - GuruFocus Wed, 18 Feb 2026 12
- Karyopharm Shareholders Approve Major Authorized Share Increase - TipRanks hu, 19 Feb 2026 21
- US$25.92: That's What Analysts Think Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Is Worth After Its Latest Results - simplywall.st hu, 14 Aug 2025 07
- Karyopharm Therapeutics Inc Shares Rise After Q4 2025 Results - AlphaStreet News hu, 12 Feb 2026 23
- KARYOPHARM THERAPEUTICS ($KPTI) Releases Q4 2025 Earnings - Quiver Quantitative hu, 12 Feb 2026 12
- Karyopharm to Participate in Baird's Biotech Discovery Series - PR Newswire Mon, 08 Dec 2025 08
- Karyopharm Therapeutics (KPTI) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance hu, 12 Feb 2026 08
- New Analyst Forecast: $KPTI Given $15 Price Target - Quiver Quantitative Wed, 18 Feb 2026 12
- How New Price Targets Are Shaping The Story For Karyopharm Therapeutics (KPTI) - Yahoo Finance Fri, 23 Jan 2026 08
- Here's Why Karyopharm Therapeutics (KPTI) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance Mon, 26 May 2025 07
- Does Karyopharm Therapeutics (KPTI) Have the Potential to Rally 521.62% as Wall Street Analysts Expect? - Yahoo Finance Mon, 19 May 2025 07
- $KPTI stock is down 14% today. Here's what we see in our data. - Quiver Quantitative Wed, 08 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 378 | 3262.0 | — | Sale at price 8.63 per share. | POULTON STUART | Officer | — | 2026-02-17 00:00:00 | D |
| 1 | 81060 | — | — | Stock Award(Grant) at price 0.00 per share. | PAULSON RICHARD A. | Chief Executive Officer | — | 2026-02-05 00:00:00 | D |
| 2 | 1626 | 10244.0 | — | Sale at price 6.30 per share. | MACOMBER LORI A | Chief Financial Officer | — | 2026-02-03 00:00:00 | D |
| 3 | 32415 | — | — | Stock Award(Grant) at price 0.00 per share. | RANGWALA RESHMA | Officer | — | 2026-01-30 00:00:00 | D |
| 4 | 32415 | — | — | Stock Award(Grant) at price 0.00 per share. | MANO MICHAEL | Officer | — | 2026-01-30 00:00:00 | D |
| 5 | 32415 | — | — | Stock Award(Grant) at price 0.00 per share. | CHENG SOHANYA ROSHAN | Officer | — | 2026-01-30 00:00:00 | D |
| 6 | 32415 | — | — | Stock Award(Grant) at price 0.00 per share. | MACOMBER LORI A | Chief Financial Officer | — | 2026-01-30 00:00:00 | D |
| 7 | 32415 | — | — | Stock Award(Grant) at price 0.00 per share. | POULTON STUART | Officer | — | 2026-01-30 00:00:00 | D |
| 8 | 50 | 352.0 | — | Sale at price 7.03 per share. | ABATE KRISTIN | Officer | — | 2026-01-28 00:00:00 | D |
| 9 | 92 | — | — | Stock Award(Grant) at price 0.00 per share. | ABATE KRISTIN | Officer | — | 2026-01-27 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 9.39M | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.21 | 0.21 | 0.21 | 0.27 |
| NormalizedEBITDA | -83.31M | -118.42M | -139.31M | -96.98M |
| TotalUnusualItems | 44.70M | 0.00 | 0.00 | -110.00K |
| TotalUnusualItemsExcludingGoodwill | 44.70M | 0.00 | 0.00 | -110.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -76.42M | -143.10M | -165.29M | -124.09M |
| ReconciledDepreciation | 340.00K | 530.00K | 621.00K | 789.00K |
| ReconciledCostOfRevenue | 6.01M | 4.94M | 5.21M | 3.40M |
| EBITDA | -38.60M | -118.42M | -139.31M | -96.98M |
| EBIT | -38.94M | -118.95M | -139.93M | -97.77M |
| NetInterestIncome | -30.02M | -12.88M | -22.64M | -25.46M |
| InterestExpense | 37.42M | 23.82M | 25.00M | 26.05M |
| InterestIncome | 7.40M | 10.94M | 2.36M | 582.00K |
| NormalizedIncome | -111.74M | -143.10M | -165.29M | -124.09M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -76.42M | -143.10M | -165.29M | -124.09M |
| TotalExpenses | 264.68M | 275.57M | 299.28M | 308.09M |
| TotalOperatingIncomeAsReported | -119.44M | -129.54M | -142.20M | -98.27M |
| DilutedAverageShares | 10.94M | 8.45M | 7.61M | 5.46M |
| BasicAverageShares | 10.94M | 8.12M | 7.61M | 5.46M |
| DilutedEPS | -17.93 | -13.95 | -18.75 | -30.30 |
| BasicEPS | -17.93 | -9.45 | -18.75 | -30.30 |
| DilutedNIAvailtoComStockholders | -76.42M | -143.10M | -165.29M | -124.09M |
| NetIncomeCommonStockholders | -76.42M | -143.10M | -165.29M | -124.09M |
| NetIncome | -76.42M | -143.10M | -165.29M | -124.09M |
| NetIncomeIncludingNoncontrollingInterests | -76.42M | -143.10M | -165.29M | -124.09M |
| NetIncomeContinuousOperations | -76.42M | -143.10M | -165.29M | -124.09M |
| TaxProvision | 57.00K | 323.00K | 369.00K | 268.00K |
| PretaxIncome | -76.36M | -142.78M | -164.92M | -123.82M |
| OtherIncomeExpense | 73.10M | -356.00K | -83.00K | -85.00K |
| OtherNonOperatingIncomeExpenses | 28.40M | -356.00K | -83.00K | -85.00K |
| SpecialIncomeCharges | 44.70M | 0.00 | 0.00 | |
| OtherSpecialCharges | -44.70M | |||
| GainOnSaleOfSecurity | -96.00K | -110.00K | ||
| NetNonOperatingInterestIncomeExpense | -30.02M | -12.88M | -22.64M | -25.46M |
| InterestExpenseNonOperating | 37.42M | 23.82M | 25.00M | 26.05M |
| InterestIncomeNonOperating | 7.40M | 10.94M | 2.36M | 582.00K |
| OperatingIncome | -119.44M | -129.54M | -142.20M | -98.27M |
| OperatingExpense | 258.67M | 270.63M | 294.06M | 304.69M |
| ResearchAndDevelopment | 143.23M | 138.75M | 148.66M | 160.84M |
| SellingGeneralAndAdministration | 115.44M | 131.88M | 145.40M | 143.85M |
| GeneralAndAdministrativeExpense | 115.44M | 131.88M | 145.40M | 143.85M |
| OtherGandA | 44.37M | 50.61M | 56.41M | 59.59M |
| SalariesAndWages | 71.07M | 81.28M | 88.99M | 84.25M |
| GrossProfit | 139.23M | 141.09M | 151.86M | 206.42M |
| CostOfRevenue | 6.01M | 4.94M | 5.21M | 3.40M |
| TotalRevenue | 145.24M | 146.03M | 157.07M | 209.82M |
| OperatingRevenue | 145.24M | 146.03M | 157.07M | 209.82M |
| Line Item | 2023-12-31 | |||
|---|---|---|---|---|
| TreasurySharesNumber | 0.00 | |||
| OrdinarySharesNumber | 8.41M | 7.66M | 7.55M | 5.05M |
| ShareIssued | 8.41M | 7.66M | 7.55M | 5.05M |
| NetDebt | 124.90M | 118.69M | 34.92M | |
| TotalDebt | 194.52M | 177.02M | 179.07M | 180.58M |
| TangibleBookValue | -186.02M | -136.21M | -16.66M | -79.67M |
| InvestedCapital | 1.36M | 34.71M | 153.45M | 89.62M |
| WorkingCapital | 64.23M | 164.44M | 284.25M | 201.89M |
| NetTangibleAssets | -186.02M | -136.21M | -16.66M | -79.67M |
| CapitalLeaseObligations | 7.15M | 6.10M | 8.97M | 11.29M |
| CommonStockEquity | -186.02M | -136.21M | -16.66M | -79.67M |
| TotalCapitalization | -23.07M | 34.71M | 153.45M | 89.62M |
| TotalEquityGrossMinorityInterest | -186.02M | -136.21M | -16.66M | -79.67M |
| StockholdersEquity | -186.02M | -136.21M | -16.66M | -79.67M |
| GainsLossesNotAffectingRetainedEarnings | -356.00K | -161.00K | -638.00K | 191.00K |
| OtherEquityAdjustments | -356.00K | -161.00K | -638.00K | 191.00K |
| RetainedEarnings | -1.56B | -1.49B | -1.34B | -1.18B |
| AdditionalPaidInCapital | 1.38B | 1.35B | 1.33B | 1.10B |
| CapitalStock | 13.00K | 12.00K | 12.00K | 8.00K |
| CommonStock | 13.00K | 12.00K | 12.00K | 8.00K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 350.44M | 376.64M | 374.83M | 384.98M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 258.17M | 307.17M | 308.92M | 311.26M |
| OtherNonCurrentLiabilities | 2.43M | 978.00K | ||
| DerivativeProductLiabilities | 12.58M | 0.00 | ||
| NonCurrentDeferredLiabilities | 73.50M | 132.48M | 132.72M | 133.00M |
| LongTermDebtAndCapitalLeaseObligation | 169.66M | 173.71M | 176.20M | 178.26M |
| LongTermCapitalLeaseObligation | 6.71M | 2.79M | 6.10M | 8.97M |
| LongTermDebt | 162.95M | 170.92M | 170.10M | 169.29M |
| CurrentLiabilities | 92.26M | 69.48M | 65.91M | 73.72M |
| OtherCurrentLiabilities | 1.64M | 1.65M | 1.85M | 678.00K |
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDeferredRevenue | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 24.86M | 3.31M | 2.87M | 2.32M |
| CurrentCapitalLeaseObligation | 438.00K | 3.31M | 2.87M | 2.32M |
| CurrentDebt | 24.43M | |||
| OtherCurrentBorrowings | 24.43M | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 13.91M | 16.51M | 19.62M | 19.69M |
| PayablesAndAccruedExpenses | 51.84M | 48.01M | 41.56M | 51.04M |
| CurrentAccruedExpenses | 46.74M | 44.88M | 38.79M | 49.43M |
| InterestPayable | 1.86M | 13.45M | 11.67M | 21.98M |
| Payables | 5.11M | 3.12M | 2.77M | 1.60M |
| AccountsPayable | 5.11M | 3.12M | 2.77M | 1.60M |
| TotalAssets | 164.42M | 240.44M | 358.17M | 305.31M |
| TotalNonCurrentAssets | 7.93M | 6.52M | 8.01M | 29.70M |
| OtherNonCurrentAssets | 1.64M | 1.64M | 633.00K | 20.14M |
| InvestmentsAndAdvances | 0.00 | |||
| NetPPE | 6.28M | 4.88M | 7.38M | 9.56M |
| AccumulatedDepreciation | -6.69M | -6.57M | -6.64M | -6.06M |
| GrossPPE | 12.97M | 11.45M | 14.02M | 15.61M |
| Leases | 4.88M | 4.88M | 5.45M | 5.45M |
| OtherProperties | 6.86M | 5.11M | 7.11M | 8.74M |
| MachineryFurnitureEquipment | 1.24M | 1.46M | 1.46M | 1.43M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 156.49M | 233.92M | 350.16M | 275.61M |
| OtherCurrentAssets | 12.24M | 11.81M | 19.82M | 14.04M |
| RestrictedCash | 30.00K | 660.00K | 1.06M | 6.35M |
| PrepaidAssets | 14.04M | |||
| Inventory | 4.74M | 3.04M | 4.22M | 4.11M |
| FinishedGoods | 477.00K | 758.00K | 976.00K | 414.00K |
| WorkInProcess | 3.54M | 1.73M | 1.88M | 1.90M |
| RawMaterials | 720.00K | 553.00K | 1.37M | 1.80M |
| Receivables | 30.77M | 26.96M | 47.09M | 22.50M |
| AccountsReceivable | 30.77M | 26.96M | 47.09M | 22.50M |
| CashCashEquivalentsAndShortTermInvestments | 108.71M | 191.44M | 277.97M | 228.62M |
| OtherShortTermInvestments | 46.24M | 139.21M | 142.78M | 38.16M |
| CashAndCashEquivalents | 62.48M | 52.23M | 135.19M | 190.46M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -127.63M | -92.72M | -149.67M | -112.83M |
| IssuanceOfDebt | 83.30M | 0.00 | 0.00 | |
| IssuanceOfCapitalStock | 0.00 | 0.00 | 189.76M | 9.90M |
| CapitalExpenditure | -142.00K | -118.00K | -5.71M | |
| InterestPaidSupplementalData | 38.59M | 21.23M | 34.45M | 15.54M |
| EndCashPosition | 62.81M | 53.19M | 136.88M | 197.44M |
| BeginningCashPosition | 53.19M | 136.88M | 197.44M | 89.12M |
| EffectOfExchangeRateChanges | -11.00K | -34.00K | -488.00K | -48.00K |
| ChangesInCash | 9.63M | -83.66M | -60.07M | 108.37M |
| FinancingCashFlow | 41.65M | 1.12M | 193.74M | 73.65M |
| CashFlowFromContinuingFinancingActivities | 41.65M | 1.12M | 193.74M | 73.65M |
| NetOtherFinancingCharges | -43.11M | 60.00M | ||
| ProceedsFromStockOptionExercised | 1.45M | 1.12M | 3.98M | 3.75M |
| NetCommonStockIssuance | 0.00 | 0.00 | 189.76M | 9.90M |
| CommonStockIssuance | 0.00 | 0.00 | 189.76M | 9.90M |
| NetIssuancePaymentsOfDebt | 83.30M | 0.00 | 0.00 | |
| NetLongTermDebtIssuance | 83.30M | 0.00 | 0.00 | |
| LongTermDebtIssuance | 83.30M | 0.00 | 0.00 | |
| InvestingCashFlow | 95.47M | 7.94M | -104.26M | 141.84M |
| CashFlowFromContinuingInvestingActivities | 95.47M | 7.94M | -104.26M | 141.84M |
| NetInvestmentPurchaseAndSale | 95.61M | 7.94M | -104.14M | 147.55M |
| SaleOfInvestment | 154.44M | 167.09M | 121.88M | 192.78M |
| PurchaseOfInvestment | -58.82M | -159.15M | -226.02M | -45.23M |
| NetIntangiblesPurchaseAndSale | 0.00 | 0.00 | -5.50M | |
| PurchaseOfIntangibles | 0.00 | 0.00 | -5.50M | |
| NetPPEPurchaseAndSale | -142.00K | 0.00 | -118.00K | -212.00K |
| PurchaseOfPPE | -142.00K | 0.00 | -118.00K | -212.00K |
| OperatingCashFlow | -127.49M | -92.72M | -149.55M | -107.12M |
| CashFlowFromContinuingOperatingActivities | -127.49M | -92.72M | -149.55M | -107.12M |
| ChangeInWorkingCapital | -302.00K | 31.42M | -19.99M | -23.19M |
| ChangeInOtherWorkingCapital | -297.00K | |||
| ChangeInOtherCurrentLiabilities | 1.05M | -2.87M | -2.32M | -1.92M |
| ChangeInOtherCurrentAssets | -1.61M | 1.96M | 1.68M | 1.45M |
| ChangeInPayablesAndAccruedExpense | 6.18M | 4.35M | -8.37M | 13.12M |
| ChangeInAccruedExpense | 4.20M | 4.00M | -9.54M | 15.96M |
| ChangeInPayable | 1.98M | 350.00K | 1.17M | -2.85M |
| ChangeInAccountPayable | 1.98M | 350.00K | 1.17M | -2.85M |
| ChangeInPrepaidAssets | -432.00K | 6.67M | -5.78M | -24.76M |
| ChangeInInventory | -1.70M | 1.18M | -118.00K | -1.46M |
| ChangeInReceivables | -3.80M | 20.12M | -5.08M | -9.62M |
| ChangesInAccountReceivables | -3.80M | 20.12M | -5.08M | -9.62M |
| OtherNonCashItems | 6.37M | 814.00K | 812.00K | 8.03M |
| StockBasedCompensation | 18.43M | 21.71M | 35.40M | 29.78M |
| AssetImpairmentCharge | 0.00 | |||
| AmortizationOfSecurities | -2.50M | -4.10M | -825.00K | 1.56M |
| DepreciationAmortizationDepletion | 340.00K | 530.00K | 621.00K | 789.00K |
| DepreciationAndAmortization | 340.00K | 530.00K | 621.00K | 789.00K |
| OperatingGainsLosses | -73.39M | -281.00K | -106.00K | |
| GainLossOnInvestmentSecurities | -28.69M | -281.00K | -106.00K | |
| NetIncomeFromContinuingOperations | -76.42M | -143.10M | -165.29M | -124.09M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for KPTI
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|